Page last updated: 2024-11-02

pioglitazone and Brain Vascular Disorders

pioglitazone has been researched along with Brain Vascular Disorders in 9 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to conduct a direct comparison of TZDs (pioglitazone and rosiglitazone) and their relationship to cardiovascular events (myocardial infarction [MI], angina, congestive heart failure [CHF], and cerebral vascular accident [CVA]) in Taiwanese patients with type 2 diabetes mellitus (DM)."3.77Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. ( Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC, 2011)
"Pioglitazone treatment rescued a third of these proteins, mainly those associated with oxidative stress, promotion of cerebrovascular vasocontractile tone, and vascular compliance."1.46Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone. ( Badhwar, A; Brown, R; Hamel, E; Haqqani, AS; Stanimirovic, DB, 2017)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's8 (88.89)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ahn, KC1
Learman, CR1
Baker, GB1
Weaver, CL1
Chung, PS1
Kim, HG1
Song, MS1
Katsiki, N1
Mikhailidis, DP1
Inzucchi, SE1
Viscoli, CM1
Young, LH1
Furie, KL1
Gorman, M1
Lovejoy, AM1
Dagogo-Jack, S1
Ismail-Beigi, F1
Korytkowski, MT1
Pratley, RE1
Schwartz, GG1
Kernan, WN1
Pantoni, L1
Badhwar, A1
Brown, R1
Stanimirovic, DB1
Haqqani, AS1
Hamel, E3
Lai, SW1
Lin, HF1
Lin, CL1
Liao, KF1
Nicolakakis, N2
Aboulkassim, T2
Ongali, B1
Lecrux, C1
Fernandes, P1
Rosa-Neto, P2
Tong, XK2
Aliaga, A1
Wang, CC1
Chen, WL1
Kao, TW1
Chang, YW1
Loh, CH1
Chou, CC2

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Cerebrovascular Reactivity (CVR) Assessed With Functional Near Infrared Spectroscopy (fNIRS) as a Biomarker of Traumatic Cerebrovascular Injury (TCVI) Measured Longitudinally After Acute TBI in Military Personnel[NCT04058132]Phase 250 participants (Anticipated)Interventional2019-08-09Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for pioglitazone and Brain Vascular Disorders

ArticleYear
Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?
    Journal of Korean medical science, 2019, Dec-02, Volume: 34, Issue:46

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Astrocytes; Brain; Cerebrovascular Disorders; Diabetes Mel

2019

Other Studies

8 other studies available for pioglitazone and Brain Vascular Disorders

ArticleYear
Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
    Diabetes care, 2017, Volume: 40, Issue:4

    Topics: Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; In

2017
Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
    Diabetes care, 2017, Volume: 40, Issue:4

    Topics: Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; In

2017
Potential New Horizons for the Prevention of Cerebrovascular Diseases and Dementia.
    JAMA neurology, 2019, 05-01, Volume: 76, Issue:5

    Topics: Cerebrovascular Disorders; Dementia; Humans; Pioglitazone; Prediabetic State; Stroke

2019
Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2017, Volume: 37, Issue:3

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Biomarkers; Blood

2017
Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes: A case-control study in Taiwan.
    Medicine, 2016, Volume: 95, Issue:31

    Topics: Aged; Case-Control Studies; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Female; Humans; Hy

2016
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Sep-10, Volume: 28, Issue:37

    Topics: Acetylcholine; Acetylcysteine; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein

2008
Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2011, Volume: 31, Issue:1

    Topics: Aging; Animals; Antioxidants; Blotting, Western; Cerebrovascular Circulation; Cerebrovascular Disord

2011
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Clinical therapeutics, 2011, Volume: 33, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; C

2011